2,178 results match your criteria Hidradenitis Suppurativa


Sexual Distress in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study.

J Clin Med 2019 Apr 18;8(4). Epub 2019 Apr 18.

Dermatology, Hidradenitis Suppurativa Clinic, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas 2, 18014 Granada, Spain.

Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease with a great impact in quality of life. However, there is little research about the impact of HS on sex life. The aims of this study are to describe the frequency of sexual distress (SD) in patients with HS and to explore potentially associated epidemiological and clinical factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8040532DOI Listing

Staphylococcus aureus and Host Immunity in Recurrent Furunculosis.

Dermatology 2019 Apr 17:1-11. Epub 2019 Apr 17.

Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.

Staphylococcus aureus is one of the severest and most persistent bacterial pathogens. The most frequent S. aureus infections include impetigo, folliculitis, furuncles, furunculosis, abscesses, hidradenitis suppurativa, and mastitis. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499184
Publisher Site
http://dx.doi.org/10.1159/000499184DOI Listing
April 2019
3 Reads

Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.

JAMA Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Importance: The overall comorbidity burden among patients with hidradenitis suppurativa (HS) has not been systematically evaluated.

Objectives: To investigate the standardized overall comorbidity burden among patients with HS and to compare it with the comorbidity burden in patients with psoriasis and a control group.

Design, Setting, And Participants: A cross-sectional analysis was conducted of 5306 patients with HS, 14 037 patients with psoriasis, and 1 733 810 controls identified using electronic health records data from October 1, 2013, through October 1, 2018. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2019.0164DOI Listing
April 2019
1 Read

Characterization of perianal fistulas in patients with hidradenitis suppurativa.

J Eur Acad Dermatol Venereol 2019 Apr 15. Epub 2019 Apr 15.

Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease characterized by recurring abscesses, nodules and draining fistulas in the intertriginous regions of the body. Anogenital involvement is present in 18.8% of HS patients. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.15629
Publisher Site
http://dx.doi.org/10.1111/jdv.15629DOI Listing
April 2019
1 Read

Migraine is not the most common comorbidity in hidradenitis suppurativa patients.

J Eur Acad Dermatol Venereol 2019 Apr 13. Epub 2019 Apr 13.

Department of dermatology, allergology and venereology, Helsinki University Central Hospital, Helsinki, Finland.

Migraine is the most common primary headache syndrome worldwide, affecting approximately 12% of the Caucasian population [1]. Migraine has been associated with various cardiovascular [2] and psychiatric co-morbidities [3], more recently inflammatory disorders such as psoriasis [4] and inflammatory bowel disease [5]. As hidradenitis suppurativa (HS) shares common comorbidity risks, we sought to investigate the possible link between migraine and HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15625DOI Listing
April 2019
1 Read

PAPASH, PsAPASH and PASS autoinflammatory syndromes: Phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens.

Br J Dermatol 2019 Apr 13. Epub 2019 Apr 13.

Department of Dermatology, APHP Hôpital St-Louis, Paris.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of skin appendages, commonly associating with other conditions including spondyloarthritis, and is a major component of severe cutaneo-articular autoinflammatory syndromes (AIS), called PAPASH (Pyogenic Arthritis, pyoderma gangrenosum/PG, Acne, HS), PsAPASH (Psoriatic Arthritis, PG, Acne, HS) and PASS (Ankylosing Spondylitis, Acne, PG and HS). The clinical phenotypes of these AIS are ill-defined and unlike PASH or PAPA syndromes, still lack any biological or genetic marker. Moreover, their optimal therapeutic management remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18003DOI Listing

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.

Front Pharmacol 2019 26;10:282. Epub 2019 Mar 26.

UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Targeted immune-modulating treatment with biological agents has revolutionized the management of immune-mediated inflammatory diseases, including rheumatologic conditions. The efficacy and tolerability of biological agents, from the initial tumour necrosis factor (TNF)-α inhibitors to the new anti-cytokine monoclonal antibodies, have dramatically changed the natural history of debilitating conditions such as rheumatoid arthritis and seronegative spondyloarthropathies. The widening use of biologics across several rheumatologic diseases has been associated with a new class of adverse events, the so-called paradoxical reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443901PMC
March 2019
2 Reads

Interrater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa.

Br J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.

Core outcome domains represent a major need in hidradenitis suppurativa/acne inversa (HS) as reliable disease classification systems and treatment outcome parameters. Thorlacius et al. reported recently that none of the HS classifications systems could be recommended when used with HS experts as raters without a preceding bedside training session. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.17982
Publisher Site
http://dx.doi.org/10.1111/bjd.17982DOI Listing
April 2019
2 Reads

Severe forms of hidradenitis suppurativa with complications in the anogenital area.

Dermatol Ther 2019 Apr 9:e12910. Epub 2019 Apr 9.

IDI-IRCCS, via dei Monti di Creta 104, 00167, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12910DOI Listing

Penile and scrotal lymphedema associated with hidradenitis suppurativa: Case report and review of surgical options.

Cir Cir 2019 ;86(1):77-80

Department of Plastic Surgery, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

Lymphedema is the result of an alteration of the lymphatic drainage, and its most common worldwide cause is filariasis. In our practice usually is associated to neoplasic, inflammatory and granulomatous processes, radiotherapy, hydroelectrolytic disbalances, and idiopathic. It can affect any part of the body, including the penis and scrotum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/CIRUE.M18000012DOI Listing
January 2019
4 Reads

The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?

Authors:
John W Frew

J Dermatolog Treat 2019 Apr 4:1-2. Epub 2019 Apr 4.

a Laboratory of Investigative Dermatology , Rockefeller University , New York , NY , USA.

The pathogenesis of hidradenitis suppurativa (HS) centers around Th17/Treg dysfunction illustrated by lesional elevation of IL-17A, IL-6, and other inflammatory mediators resulting in a chronic feed-forward inflammatory cascade. Similar inflammatory mechanisms have been identified in psoriasis and rheumatoid arthritis (RA) in which traditional immunosuppressants (including methotrexate) are routinely used with reasonable levels of disease control. Methotrexate's mechanism of action in these instances includes downregulation of the Th17 axis via alterations in dendritic cell and T-cell activity and maturation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1
Publisher Site
http://dx.doi.org/10.1080/09546634.2019.1601668DOI Listing
April 2019
2 Reads

Adalimumab every other week combined with dexamethasone pulses for the treatment of refractory hidradenitis suppurativa.

Dermatol Ther 2019 Apr 4:e12885. Epub 2019 Apr 4.

Dermatology Department, Hidradenitis Suppurativa Clinic, Hospital Universitario Virgen de las Nieves, Granada, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12885DOI Listing
April 2019
1 Read

Off-label studies on apremilast in dermatology: a review.

J Dermatolog Treat 2019 Apr 2:1-10. Epub 2019 Apr 2.

a Division of Dermatology, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.

Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1589641DOI Listing
April 2019
5 Reads

Prolonged clindamycin and rifampicin for hidradenitis suppurativa: resist to prevent resistance.

Authors:
R Hambly B Kirby

Br J Dermatol 2019 Apr;180(4):702-703

The Charles Centre, Department of Dermatology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17615DOI Listing

The epidemiology of hidradenitis suppurativa: what do we know?

Authors:
G Shalom A D Cohen

Br J Dermatol 2019 Apr;180(4):712-713

Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 151, Beer Sheva 84101, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17249DOI Listing

Lack of photographic documentation undermines assessment of hidradenitis suppurativa phenotypes: reply from the author.

Authors:
J W Frew

Br J Dermatol 2019 Mar 29. Epub 2019 Mar 29.

Laboratory for Investigative Dermatology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, U.S.A.

We thank Dr van Straalen and Dr van der Zee for their response to our article. We agree that exploring genotype-phenotype correlation in inherited hidradenitis suppurativa (HS) is an important step in improving our understanding of the disease and optimizing patient care. We also acknowledge that as an 'exploratory' analysis there are limitations in our methodology of establishing phenotypes that are inherent in compiling limited clinical information with lack of face-to-face clinical examination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17934DOI Listing

Proceeding report of the Third Symposium on Hidradenitis Suppurativa Advances (SHSA) 2018.

Exp Dermatol 2019 Mar 29. Epub 2019 Mar 29.

Department of Medicine, Division of Dermatology, University of Toronto, Toronto, ON, Canada.

The 3 Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on October 12-14, 2018 at the Women's College Hospital in Toronto, Ontario, Canada. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This cross-disciplinary meeting with experts from around the world was an opportunity to discuss the most recent advances in the study of hidradenitis suppurativa pathogenesis, epidemiology, classification, scoring systems, radiologic diagnosis, treatment approaches, and psychologic assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13928DOI Listing
March 2019
1 Read

Hidradenitis suppurativa associated with systemic lupus erythematosus and psoriasis: a therapeutical challenge.

G Ital Dermatol Venereol 2019 Mar 29. Epub 2019 Mar 29.

Unità Operativa di Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06209-6DOI Listing
March 2019
1 Read

Hidradenitis suppurativa: A systematic review and meta-analysis of therapeutic interventions.

Indian J Dermatol Venereol Leprol 2019 Mar 20. Epub 2019 Mar 20.

Department of Trauma and Orthopaedic Surgery, Montpellier University Hospital, Montpellier, France.

Hidradenitis suppurativa is a chronic inflammatory condition that affects skin regions bearing apocrine glands. Although hidradenitis suppurativa is difficult to treat and cure, the currently available treatments are directed toward managing the lesions and associated symptoms. This review presents an evidence-based outline of the available treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_69_18DOI Listing

High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey.

Br J Dermatol 2019 Mar 28. Epub 2019 Mar 28.

RésoVerneuil.

Garg et al. recently pinpointed the fact that cannabis use was more common in HS patients (1.2%) compared to the general population (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17930DOI Listing
March 2019
2 Reads

Pain perception in patients with Hidradenitis Suppurativa.

Br J Dermatol 2019 Mar 28. Epub 2019 Mar 28.

Department of Dermatology, Zealand University Hospital, Roskilde; Health Sciences Faculty, University of Copenhagen, Denmark.

Background: Pain is a prominent symptom of Hidradenitis suppurativa (HS) and has been defined as a domain in the Core Outcome Set for the disease. In addition, quality and intensity of pain is influenced by depression and anxiety both of which are associated with HS.

Objectives: To describe HS-related pain quantitatively as well as qualitatively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17935DOI Listing

Pilonidal sinus disease: An intergluteal localization of hidradenitis suppurativa/acne inversa: A cross-sectional study among 2465 patients.

Br J Dermatol 2019 Mar 27. Epub 2019 Mar 27.

ResoVerneuil, Paris, France.

Background: Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules, chronic abscesses and tunnels (fistulae and sinuses). The association with pilonidal sinus disease is frequently reported but not well documented.

Objective: To determine the prevalence and characteristics of inflammatory skin lesions located in the intergluteal fold (IGF) of HS patients. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.17927
Publisher Site
http://dx.doi.org/10.1111/bjd.17927DOI Listing
March 2019
2 Reads

Even Mild Hidradenitis Suppurativa Impairs Quality of Life.

Br J Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Hidradenitis suppurativa (HS) is a chronic, inflammatory condition characterized by recurrent abscesses and scarring. The pain, malodorous discharge and cosmetic aspects of the lesions in HS can impair quality of life. The Dermatology Life Quality Index (DLQI) is a validated and reliable measure that assesses the impact of skin disease on quality of life (QoL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17928DOI Listing
March 2019
2 Reads

Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo-Controlled, PIONEER Trials.

Br J Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Harvard Medical School and Beth Israel Deaconess Hospital, Boston, MA, United States.

Background: Weekly adalimumab (Humira ) is approved for treatment of hidradenitis suppurativa (HS) based on the 12-week, placebo-controlled periods of the two, phase-3 PIONEER trials.

Objectives: From PIONEER integrated trial results, we evaluated the optimal medium-term adalimumab maintenance dosing strategy in moderate-to-severe HS.

Methods: Each trial had two double-blind periods; 12-week Period A and 24-week Period B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17919DOI Listing

The microbiome of tunnels in hidradenitis suppurativa patients.

J Eur Acad Dermatol Venereol 2019 Mar 25. Epub 2019 Mar 25.

Department of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.

Background: Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease defined by recurrent nodules, tunnels and scarring involving the intertriginous regions. Recent Next Generation Sequencing (NGS) studies suggest genera such as Prevotella spp., Peptoniphilus spp. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.15597
Publisher Site
http://dx.doi.org/10.1111/jdv.15597DOI Listing
March 2019
7 Reads

KITTEN following CAT on the long-term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives.

Br J Dermatol 2019 Mar 25. Epub 2019 Mar 25.

Department of Dermatology, Roskilde Zealand University Hospital, Roskilde, Denmark.

We greatly appreciate the concept of Critically Appraised Topics (CATs) in your excellent journal. The format is very useful in the clinical management of cases and may change routine concepts. In view of the recent CAT on the safety of extended use of rifampicin in the management of hidradenitis suppurativa (HS) we would like to suggest the addition of an important Knowledge-based ITeraTion of Evidence Notification (KITTEN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17900DOI Listing

[Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].

Rev Esp Salud Publica 2019 Mar 25;93. Epub 2019 Mar 25.

Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain.

Objective: Immune-mediated inflammatory diseases (IMID) are chronic and highly disabling diseases that share inflammatory sequences and immunological dysregulations. Considered as a disease in itself, the prevalence of IMID is virtually unknown. The aim of this study was to assess the prevalence of 10 selected UDI, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, hidradenitis suppurativa, sarcoidosis and uveitis in Spain. Read More

View Article

Download full-text PDF

Source
March 2019
4 Reads

Matrix remodeling and MMP expression/activation is associated with hidradenitis suppurativa skin inflammation.

Exp Dermatol 2019 Mar 23. Epub 2019 Mar 23.

EA 7509 IRMAIC, UFR medicine, University of Champagne-ArdenneReims, France.

Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle, associated with considerable tissue remodeling. Although abnormal cytokines expression was detected both in perilesional and in uninvolved skin, up to now there is no model allowing a better understanding of the implicit inflammatory mechanisms in HS. The aim of this study was to investigate the inflammatory response in HS skin by mean of an ex vivo model culture. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.13919
Publisher Site
http://dx.doi.org/10.1111/exd.13919DOI Listing
March 2019
7 Reads

Validation of a Hidradenitis Suppurativa Self-Assessment Tool.

J Cutan Med Surg 2019 Mar 22:1203475419839965. Epub 2019 Mar 22.

1 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Background:: Hidradenitis suppurativa (HS) is a debilitating dermatologic condition presenting with recurrent abscesses. While there are multiple scales to determine HS severity, none are designed for self-administration. A validated severity self-assessment tool may facilitate survey research and improve communication by allowing patients to objectively report their HS severity between clinic visits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419839965DOI Listing
March 2019
3 Reads

Patient Perspectives: What is hidradenitis suppurativa (HS)?

Authors:

Pediatr Dermatol 2019 03;36(2):249-250

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13832DOI Listing

Metformin use in hidradenitis suppurativa.

J Dermatolog Treat 2019 Mar 20:1-3. Epub 2019 Mar 20.

a The Charles Centre, Department of Dermatology , St Vincent's University Hospital , Dublin , Ireland.

Background: Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory disease, associated with metabolic syndrome, obesity and insulin resistance. Metformin, an oral hypoglycaemic agent, may play an important role in delaying or preventing the onset of diabetes and metabolic syndrome. Metformin has been reported as having efficacy in HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1592100DOI Listing
March 2019
5 Reads
1.764 Impact Factor

Psoriasis treatment in patients with sickle cell disease.

Cutis 2018 Feb;102(2):93-94

Department of Dermatology, The University of Tennessee Health Science Center, Memphis, USA.

Plaque psoriasis is a chronic inflammatory disease driven by the proliferation of T cells and the production of several immunomodulators such as tumor necrosis factor (TNF) α. Tumor necrosis factor α plays a key role in multiple inflammatory conditions, including psoriatic arthritis, rheumatoid arthritis, and hidradenitis suppurativa. We present a patient with plaque psoriasis and sickle cell disease who began treatment with the TNF-α inhibitor adalimumab. Read More

View Article

Download full-text PDF

Source
February 2018
8 Reads

Defining Fistular Patterns in Hidradenitis Suppurativa: Impact in the Management.

Dermatol Surg 2019 Mar 18. Epub 2019 Mar 18.

Department of Dermatology, Hospital de Manises, Valencia, Spain.

Background: Recent studies suggest that there are different fistular subtypes in hidradenitis suppurativa (HS) patients who are associated with variable therapeutic outcomes.

Objective: To describe clinical and ultrasound features that characterize the different fistular patterns in HS and to evaluate the response to medical therapies.

Methods: A retrospective study developed by a well-recognized center specialized in HS analyzing both clinical and ultrasound (US) aspects of fistular structures in HS patients was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000001916DOI Listing
March 2019
3 Reads

Commentary on Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa.

Dermatol Surg 2019 Apr;45(4):527-528

Bennett Surgery Center, Inc, Santa Monica, California David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California Keck School of Medicine, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000001924DOI Listing

Multiple self-healing palmoplantar carcinoma: An aberrance of the inflammasome.

JAAD Case Rep 2019 Mar 1;5(3):261-263. Epub 2019 Mar 1.

Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403110PMC
March 2019
1 Read

Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, Concomitant Conditions, and Diagnostic Delay in a University Teaching Hospital in Buenos Aires, Argentina.

Actas Dermosifiliogr 2019 Mar 15. Epub 2019 Mar 15.

Servicio de Dermatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Background: Hidradenitis suppurativa is a chronic recurrent systemic inflammatory disease that mainly involves large skin folds. It develops when pilosebaceous units become blocked, leading to the formation of painful nodules, abscesses, fistulas, and scarring. The impact of this disease on quality of life is great. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2019.01.004DOI Listing

Treatment of Hidradenitis Suppurativa with Extensive Resection of the Lesion and Coverage with Perforator Flaps of the Lateral Thoracic Wall (Lateral Thoracic Artery, Thoracodorsal Artery Perforators).

Plast Reconstr Surg Glob Open 2019 Feb 5;7(2):e2096. Epub 2019 Feb 5.

Department of Plastic Surgery, SOMER Clinic, Rionegro, Colombia.

Stage IV hidradenitis suppurativa in the axilla is a chronic disease in which the removal of the affected area and a reconstruction with disease free skin is the definitive treatment; however there is some controversy about the technique to be used in this reconstruction. Studies show superiority in wide resections, and coverage with flaps rather than grafts. The use of pedicle flaps of lateral thoracic artery perforators and thoracodorsal artery perforators has demonstrated superior performance to other techniques in postsurgical follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GOX.0000000000002096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416117PMC
February 2019

Mast cells in hidradenitis suppurativa: a clinicopathological study.

Arch Dermatol Res 2019 May 15;311(4):331-335. Epub 2019 Mar 15.

Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.

Mast cells (MC) have been observed in hidradenitis suppurativa (HS) lesions. Their potential role in the pathogenesis of HS is unknown. The aim of this study was to assess the number and distribution MC in HS lesions, and its association with disease and itch severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-019-01910-3DOI Listing
May 2019
2 Reads

The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa.

J Am Acad Dermatol 2019 Apr;80(4):1137-1139

Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183265
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.09.045DOI Listing
April 2019
2 Reads

Reply to comment: Guselkumab in the treatment of severe hidradenitis suppurativa.

Authors:
M Kovacs M Podda

J Eur Acad Dermatol Venereol 2019 Mar 15. Epub 2019 Mar 15.

Klinikum Darmstadt GmbH, Heidelberger Landstrasse 379, 64297, Darmstadt.

We completely agree with Dr. Frew's comment that comparing results of clinical trials requires consistent outcome measures. HiSCR has been used as a primary endpoint outcome measure in multiple RCTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15573DOI Listing

Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease.

Authors:
J W Frew

J Eur Acad Dermatol Venereol 2019 Mar 15. Epub 2019 Mar 15.

Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15572DOI Listing

Lack of photographic documentation undermines assessment of Hidradenitis Suppurativa phenotypes.

Br J Dermatol 2019 Mar 15. Epub 2019 Mar 15.

Department of Dermatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Recently a study conducted by Frew et al. was published in the British Journal of Dermatology. Frew et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17887DOI Listing

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management.

J Am Acad Dermatol 2019 Mar 11. Epub 2019 Mar 11.

Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec, 2880 Chemin des Quatre-Bourgeois, Quebec, QC G1V 4X7, Canada.

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.067DOI Listing

Comment on "Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes".

J Am Acad Dermatol 2019 Mar 11. Epub 2019 Mar 11.

Department of Clinical Medicine and Surgery - Section of Dermatology - University of Naples Federico II Naples - Itlay.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.066DOI Listing
March 2019
1 Read

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management.

J Am Acad Dermatol 2019 Mar 11. Epub 2019 Mar 11.

Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec, 2880 Chemin des Quatre-Bourgeois, Quebec, QC G1V 4X7, Canada.

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.068DOI Listing

Commentary: Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.

Authors:
John W Frew

Front Immunol 2019 25;10:302. Epub 2019 Feb 25.

Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397846PMC
February 2019

Vitamin D and the Skin: A Review for Dermatologists.

Actas Dermosifiliogr 2019 Mar 8. Epub 2019 Mar 8.

Servicio de Dermatología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, España.

In recent years, the growing interest in the role played by vitamin D in skin disease has given rise to the publication of many studies of the relationship between this vitamin and certain skin conditions. As dermatologists, we need to understand, among other aspects, how vitamin D is synthesized and the main sources in humans, as well as plasma levels and the factors that can modify them. Of particular interest are the latest discoveries about the role of vitamin D in skin diseases such as lupus erythematosus, ichthyosis, atopic dermatitis, hidradenitis suppurativa, acne, alopecia areata, androgenetic alopecia, melanoma, and nonmelanoma skin cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00017310183053
Publisher Site
http://dx.doi.org/10.1016/j.ad.2018.08.006DOI Listing
March 2019
11 Reads

Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.

Ther Adv Chronic Dis 2019 1;10:2040622319830646. Epub 2019 Mar 1.

Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin, manifesting in chronic, recurrent painful pustules, nodules, boils and purulent draining abscesses. Our current understanding of the pathogenesis of the disease is incomplete. This review aims to identify available treatment options in HS and discuss the pharmacological mechanisms through which such agents function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040622319830646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399757PMC
March 2019
2 Reads